Identifying biomarkers for Alzheimer's disease in the Chinese population
Official title: Identifying Biomarkers in Alzheimer's Disease
Run by Chinese University of Hong Kong · NCT05655650 · Data updated 2026-11-12
This study is trying to find specific signs in blood and brain scans that can help detect Alzheimer's disease earlier in people from the Chinese community.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong, Hong Hong) |
| Status | Recruiting |
| Started | September 1, 2018 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | September 18, 2026 |
| Trial ID | NCT05655650 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals of Chinese ethnicity with a clinical diagnosis of probable Alzheimer's disease.
✕Probably not a fit
Patients with non-Alzheimer's dementia or contraindications for MRI or PET scans may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort study aims to identify biomarkers associated with Alzheimer's disease (AD) in a local Chinese population. Participants will undergo a series of cognitive assessments, blood tests, brain MRI scans, brain PET scans, and retinal imaging at baseline and during six yearly follow-ups. The study hypothesizes that blood-based proteomics, retinal imaging, and advanced imaging techniques can enhance the accuracy of early detection and staging of AD. By focusing on early detection, the study seeks to contribute to the understanding of AD progression and potential interventions.
Why it matters
Potential benefit: If successful, this study could lead to improved early detection methods for Alzheimer's disease, allowing for timely interventions.
How similar studies have gone: Other studies have shown promise in identifying biomarkers for Alzheimer's disease, but this specific approach focusing on the Chinese population is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Chinese ethnicity * \[For dementia group, clinical diagnosis of "probable Alzheimer's disease" according to recommendation from the National Institute on Aging-Alzheimer's Association workgroups (NIA-AA) Exclusion Criteria: * Clinical diagnosis of non-AD dementia * contraindication for MRI or PET
Where it's running
-
Chinese University of Hong Kong
Hong Kong, Hong Hong, Hong Kong Recruiting
Study contacts
- Study coordinator: Pualine Kwan
- Email: paulinekwan@cuhk.edu.hk
- Phone: +852 26352160
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lived Experience Narratives in Dementia
This project tests a digital Online LEND Intervention that shares dementia patients’ and caregivers’ lived experiences to see if it helps wellbeing and connection.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Tau changes after hip or knee replacement surgery
Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.
-
Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia
This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.
-
Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s
We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.
-
Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease
This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.